Brief: Abcellera Announces First Patients Dosed In Phase 2 Portion Of Its Phase 1/2 Clinical Trial Of Abcl635 For The Treatment Of Vasomotor Symptoms Due To Menopause
Jan 12 (Reuters) - Abcellera Biologics Inc ABCL.O: ABCELLERA ANNOUNCES FIRST PATIENTS DOSED IN PHASE 2 PORTION OF ITS PHASE 1/2 CLINICAL TRIAL OF ABCL635 FOR THE TREATMENT OF VASOMOTOR SYMPTOMS DUE TO MENOPAUSE ABCELLERA BIOLOGICS INC - ANTICIPATES TOP-LINE RESULTS IN Q3 2026 Source text: ID:nBw9Gjzr2a Further company coverage: ABCL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AbCellera Biologics
See all newsAbCellera Biologics Inc. reports results for the quarter ended September 30 - Earnings Summary
Canada's AbCellera Q3 revenue beats analyst estimates
Factbox: Pharma sector doubles down on AI to slash costs, timelines
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce